Sort by:
Need a comprehensive medical report on "Boehringer Ingelheim"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 25
- Registration Number
- NCT02248259
- Locations
- 🇰🇷
1289.23.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
Effect of BIIL 284 BS on Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 53
- Registration Number
- NCT02249338
Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type
Phase 2
Completed
- Conditions
- Alzheimer Disease
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 362
- Registration Number
- NCT02249403
Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)
Phase 1
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Drug: High dose of BIIL 284 BS tabletsDrug: Low dose of BIIL 284 BS tabletsDrug: Placebo
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26
- Registration Number
- NCT02247375
Comparison of the Effect of Tipranavir and Ritonavir or Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Zidovudine in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT02249416
Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer Type
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 54
- Registration Number
- NCT02249351
Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1029
- Registration Number
- NCT02248142
Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency
Phase 1
Completed
- Conditions
- Hepatic Insufficiency
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02249442
Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir
Phase 2
Completed
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02249130
The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial Asthma
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 38
- Registration Number
- NCT02249312